FANCD2 & the Fanconi Anemia Tumor Suppressor Pathway Shayna Purcell Joo et al., 333 (6040): 312-316.

Slides:



Advertisements
Similar presentations
Medical Mystery Patient X. Symptoms 0 Patient’s Symptoms: 0 Possible Diseases/Disorders: 0 Final Diagnosis:
Advertisements

SICKLE CELL DISEASE Sickle cell anemia.
Cancer: a genetic disease of inherited and somatic mutations n Gene mutations and/or genetic instability are involved in many cancers. n Viruses and environmental.
TSC2 and Tuberous Sclerosis Complex Disease Laura Koontz Biology 169.
Fanconi Anemia & FANCD2
HNPCC and MLH1 Qi Peng Cancer Biology March 30 th, 2006.
ZAFIA ANKLESARIA Role of BMPR1A in Juvenile Polyposis Syndrome Biology 169.
Xeroderma Pigmentosum, XPF and Nucleotide Excision Repair By Crystal Stanford.
FANCD2 FANCONI ANEMIA PROTEIN COMPLEMENTATION GROUP D2 by Meredith Binkley.
Neurofibromatosis 1 von Recklinghausen Syndrome Kristin Neitzke.
BRCA2 Blue: Rad51; Green: BRCA2
von Hippel-Lindau Syndrome (VHL)
ATM, Ataxia Telangiectasia, & Cancer
XPF Nucleotide Excision Repair. Xerderma Pigmentosum (XP) UV Light Sensitivity Early Age Freckling Severe Sunburning Keratosis Neurological defects Non-melonoma.
Ataxia- telangiectasia Mutated (ATM) Brooke Register.
HISTORY OF MEDICAL BIOTECHNOLOGY CHANGES IN THE LAST 15 YEARS.
- When DNA Mutates. MUTATION A heritable change in the nucleotide sequence of an organism’s DNA.
DNA Repair and Cancer. Genome Instability Science, 26 July 2002, p. 544.
Investigating the genetic instability and expression of four DNA repair related proteins in the peripheral lymphocytes of 36 untreated lung cancer patients.
BRCA2 Clark Cunningham March 26, 2015 BIOL445 American Cancer Society, eastcancer/make-a-pink-ribbon-lapel-pin,
Bloom’s Syndrome and Bloom helicase Alexandra Otto March 16, 2004.
National Heart, Lung, and Blood Institute Cancer Research Opportunities Liana Harvath, NHLBI U.S. Department of Health and Human Services National Institutes.
MYC’s role in Osteosarcoma & Lymphoma
LEANNA BROOKS BRG1: LUNG CANCER. LUNG CANCER WHAT DOES THIS HAVE TO DO WITH BRG1? LOH in chromosome 19 is frequent in NSLC tumors BRG1 is very frequently.
BRCA1 and Breast Cancer Madeline Ryan 3/17/2015.
Definition of Xeroderma Pigmentosum: XP XP, first described in 1874, is a rare genetic defect in the nucleotide excision repair mechanism. It is characterized.
What is sickle cell disease? Sickle cell disease is a disorder that affects.
BRCA1: Tumor Suppression and Breast Cancer A breast cancer cell dividing.
Molecular Basis for Relationship between Genotype and Phenotype DNA RNA protein genotype function organism phenotype DNA sequence amino acid sequence transcription.
Patched is a 12 pass transmembrane receptor: Patched is the receptor for the key signaling protein Hedgehog.
Smad4 in Colon & Pancreatic Cancers
A blood disorder Ray Rega, Ryan Molter, Ryan Kosciolek.
Breast Cancer and BRCA2. 1 million women worldwide diagnosed. 1 out of 12 women in Western Europe and the United States 30% mortality rate Highest cause.
BMPR1A Bone Morphogenetic Protein Receptor 1 A (Juvenile Polyposis & Colon Cancer) Hallie Wieters.
Bonny Blackard Biology 169 April 4, 2006
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 50 Gene Therapy and Pharmacogenomics.
Genetic Screening and Genetic Testing Risks and Benefits of Knowing Your Genetic Makeup Julie Hopp Genetic Screening: Who Should Be Tested CDC’s 2004 Science.
TSC1 and Facial Angiofibromas
Natasha Adlakha Bio445. Discovery in Breast Cancer Reverse Genetics BReast CAncer Gene Chromosome 13 Tumor suppressor gene Penetrance Familial,
NF1 (Neurofibromatosis Type 1) Greg Hogan Ribbon Representation of NF1-333 Scheffzek, et al. (The EMBO Journal Vol. 17,pp , 1998) Structural.
Fanconi Anemia Anthony Winchell. What is Fanconi Anemia?
Thalassemia Ms. Hoge Jane Doe. What is Thalassemia Blood disorder that is inherited, in which the body makes an abnormal form of hemoglobin. - hemoglobin.
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
KAITLIN BANNON SICKLE CELL DISEASE. WHAT IS SICKLE CELL DISEASE? WHERE DID IT COME FROM?
Faculdade de Medicina da Universidade de Coimbra Curso de Medicina 1º Ano Ano lectivo 2009/2010.
Role of the p21 Protein in the Fanconi Anemia (FA) Pathway
Duchenne Muscular Dystrophy By: Callia Ricozzi. What is Muscular Dystrophy?  The deterioration of the muscles  Dystrophin not made  gene mutation 
BLOOM HELICASE (and BLOOM SYNDROME)
Xeroderma Pigmentosum (XPF) Cara Mitchell. Characteristics of XP  Extreme photosensitivity  Early onset of skin cancers  Blistering of skin from sun.
HCDC4 & Endometrial Carcinoma Diana Rhyne. hCDC4 – Gene Information  Homologs in S. cervisiae, Drosophilia, and C. elegans  Tumor Suppressor  Expressed.
Biomedical Therapies Foundation Standard 1: Academic Foundation
and its role in FA and other Cancers
FANCD2: Fanconi Anemia and Cancer
FANCD2 and Fanconi’s Anemia
BRCA1 Breast Cancer.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
The Role of MSH2 in Hereditary Non-Polyposis Colon Cancer
BIOLOGY 12 Cancer.
George-Lucian Moldovan, Alan D. D'Andrea  Cancer Cell 
Relationship between Genotype and Phenotype
Ataxia telangiectasia and the Role of ATM
DNA to Genes to Genomes J.W. Prokop et al Physiological Genomics  2018, 50,
Noralane M Lindor  Clinical Gastroenterology and Hepatology 
Volume 46, Issue 2, Pages (April 2012)
BRCA1 cooperates in the Fanconi anemia/BRCA1 pathway.
Fanconi Anemia (Cross)linked to DNA Repair
History & its significance
TGF-β Pathway Inhibition Signals New Hope for Fanconi Anemia
FANCD2 Hurdles the DNA Interstrand Crosslink
Cooperation of the FA and BRCA1/2 proteins in a common ICL repair pathway. Cooperation of the FA and BRCA1/2 proteins in a common ICL repair pathway. Stalling.
Presentation transcript:

FANCD2 & the Fanconi Anemia Tumor Suppressor Pathway Shayna Purcell Joo et al., 333 (6040):

Fanconi anemia (FA) is a rare autosomal recessive disorder characterized by genomic instability Moldovan and D’Andrea, Annu. Rev. Genet :224

Disruption of the FA pathway causes chromosomal breakages and hypersensitivity to DNA interstrand crosslinks (ICLs) Deans, Nature Reviews Cancer 11, (July 2011) Chang, BMC Medical Genomics. 2014;7:24

Clinical features of the disorder include: developmental defects, early-onset bone marrow failure & cancer predisposition Fanconi Anemia: Guidelines for Diagnosis and Management (2008)Fanconi Anemia Research Fund, Inc.

Following DNA damage, ATR activates the FA core complex; FANCD2-I is ubiquitinated and localized to chromatin foci Wang, Nature Structural & Molecular Biology 15, (2008)

Ghosal and Chen, Translational Cancer Research, Vol 2, No 3 (June 2013) FANCD2 ubiquitination initiates DNA repair through Nucleotide Excision Repair, Translesion Synthesis, and Homologous Recombination

In mice: Fancd2 -null mutant phenotype includes microphtalmia, perinatal lethality, and tumor development Houghtaling, Genes & Development, 17:2021–2035 © 2003

In humans: splicing mutations of FANCD2 predominate, leading to residual FANCD2 protein in cells Kalb, the American Journal of Human Genetics, Vol. 80, Issue 5, p895–910, May 2007

Long-term treatments of FA: blood and marrow stem cell transplant, androgen therapy, synthetic growth factors, or gene therapy MacMillan, November 15, 2013; Blood: 122 (21)

References "Fanconi Anemia, Complementation Group D2; FANCD2." Online Mendelian Inheritance in Man. Johns Hopkins University, 26 June Web. 19 Mar "FA Fact Sheet." Fanconi Anemia Research Fund, Inc. 1 Feb Web. 20 Mar Houghtaling, Scott. "Epithelial Cancer in Fanconi Anemia Complementation Group D2 (Fancd2) Knockout Mice." Genes & Development 17 (2003): Cold Spring Harbor Laboratory Press. Web. 18 Mar "How Is Fanconi Anemia Treated?" NIH National Heart, Lung and Blood Institute. U.S. Department of Health & Human Services, 1 Nov Web. 26 Mar Kalb, Reinhard. "Hypomorphic Mutations in the Gene Encoding a Key Fanconi Anemia Protein, FANCD2, Sustain a Significant Group of FA-D2 Patients With Severe Phenotype." American Journal of Human Genetics 80.5 (2007): ScienceDirect. Web. 22 Mar Moldovan, George-Lucian, and Alan D. D'Andrea. "How the Fanconi Anemia Pathway Guards the Genome." Annual Review of Genetics 43 (2009): Annual Reviews. Web. 19 Mar Pickering, Anna et al. “Advances in the Understanding of the Fanconi Anemia Tumor Suppressor Pathway.” Cancer Biology & Therapy (2013): 1089–1091. PMC. Web. 26 Mar